About two dozen pharmaceutical firms are pursuing medicines for hepatitis C that could make treatment far more effective and less taxing. The drugs, including Vertex Pharmaceuticals' telaprevir and Merck & Co.'s boceprevir, could give hope to an estimated 300,000 hepatitis C patients who have not responded to existing treatment.

Related Summaries